Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Treatments and therapeutic protocols for the recovery of an asphyxiated new-born: A review of pre-clinical and clinical studies in human neonates and in different animal models

Paloma Islas-Fabila, Hector Orozco-Gregorio, Patricia Roldan-Santiago, Marilyn Waytula, Milagros Gonzalez-Hernandez, Xochil Vega-Manriquez, Carlos Antonio Jimenez-Collado, Herlinda Bonilla-Jaime

. 2022 ; 67 (6) : 271-297.

Status minimální Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc22023146

The objective of this review is to ascertain the advantages and disadvantages of several treatments and therapeutic protocols that have been used for the prevention and treatment of perinatal asphyxia in human neonates and in different animal models. Perinatal asphyxia is one of the main causes of mortality worldwide and is an important factor in triggering physio-metabolic disorders that result in serious neurological consequences and learning disorders not only in human foetuses and neonates, but also in animals. In recent years, the search for new pharmacological protocols to prevent and reverse physio-metabolic disorders and brain damage derived from perinatal asphyxia has been and continues to be the subject of intense research. Currently, within these pharmacological protocols, therapeutic strategies have been evaluated that use respiratory and hormonal stimulants, as well as hypothermic therapies in combination with other putative neuroprotective agents. Similarly, energy supplements have been evaluated with the objective of preventing perinatal asphyxia and treating new-borns with this condition, and to decrease the incidence of neonatal and foetal deaths associated with it. However, despite these promising advances, this pathology has persisted, since the administration of these therapies in low doses may not exert a neuroprotective effect or, in high doses, can trigger adverse effects (such as reduced cardiac contractility, reduced cerebral blood flow, poor perfusion, sympathetic and neuroendocrine stimulation, and increased blood viscosity) in human foetuses and neonates as well as in different animal models (rats, piglets, sheep and rabbits). Therefore, it is important to determine the minimum effective dose with which these therapies exert a neuroprotective effect, as well as the mode of administration, the duration of therapy, etc. Therefore, until a powerful strategy is found to improve the consequences of suffocation, this topic will continue to be the subject of intensive research in the future.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22023146
003      
CZ-PrNML
005      
20221007152706.0
007      
cr|cn|
008      
221007s2022 xr a fs 000 0|eng||
009      
AR
024    7_
$a 10.17221/43/2021-VETMED $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Islas-Fabila, Paloma $u Biological Sciences and Health, Universidad Autónoma Metropolitana, México City, México
245    10
$a Treatments and therapeutic protocols for the recovery of an asphyxiated new-born: A review of pre-clinical and clinical studies in human neonates and in different animal models / $c Paloma Islas-Fabila, Hector Orozco-Gregorio, Patricia Roldan-Santiago, Marilyn Waytula, Milagros Gonzalez-Hernandez, Xochil Vega-Manriquez, Carlos Antonio Jimenez-Collado, Herlinda Bonilla-Jaime
504    __
$a Literatura
520    9_
$a The objective of this review is to ascertain the advantages and disadvantages of several treatments and therapeutic protocols that have been used for the prevention and treatment of perinatal asphyxia in human neonates and in different animal models. Perinatal asphyxia is one of the main causes of mortality worldwide and is an important factor in triggering physio-metabolic disorders that result in serious neurological consequences and learning disorders not only in human foetuses and neonates, but also in animals. In recent years, the search for new pharmacological protocols to prevent and reverse physio-metabolic disorders and brain damage derived from perinatal asphyxia has been and continues to be the subject of intense research. Currently, within these pharmacological protocols, therapeutic strategies have been evaluated that use respiratory and hormonal stimulants, as well as hypothermic therapies in combination with other putative neuroprotective agents. Similarly, energy supplements have been evaluated with the objective of preventing perinatal asphyxia and treating new-borns with this condition, and to decrease the incidence of neonatal and foetal deaths associated with it. However, despite these promising advances, this pathology has persisted, since the administration of these therapies in low doses may not exert a neuroprotective effect or, in high doses, can trigger adverse effects (such as reduced cardiac contractility, reduced cerebral blood flow, poor perfusion, sympathetic and neuroendocrine stimulation, and increased blood viscosity) in human foetuses and neonates as well as in different animal models (rats, piglets, sheep and rabbits). Therefore, it is important to determine the minimum effective dose with which these therapies exert a neuroprotective effect, as well as the mode of administration, the duration of therapy, etc. Therefore, until a powerful strategy is found to improve the consequences of suffocation, this topic will continue to be the subject of intensive research in the future.
700    1_
$a Orozco-Gregorio, Hector $u Private Professional Practice, México City, México
700    1_
$a Roldan-Santiago, Patricia $u Reproduction Department, Faculty of Veterinary Medicine and Zootechnics, Universidad Nacional Autónoma de México, México City, México
700    1_
$a Waytula, Marilyn $u School of Veterinary Medicine and Zootechnics, Universidad del Valle de México, Coyoacán, Ciudad de México, México
700    1_
$a Gonzalez-Hernandez, Milagros $u Faculty of Agronomy and Veterinary, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México
700    1_
$a Vega-Manriquez, Xochil $u Faculty of Agronomy and Veterinary, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México
700    1_
$a Jimenez-Collado, Carlos Antonio $u Laboratorios Manuell S.A., Morelos, México City, México
700    1_
$a Bonilla-Jaime, Herlinda $u Department of Reproductive Biology, Universidad Autónoma Metropolitana, México City, México
773    0_
$t Veterinární medicína $x 0375-8427 $g Roč. 67, č. 6 (2022), s. 271-297 $w MED00177041
910    __
$a ABA008 $b online $y 0 $z 0
990    __
$a 20221007151552 $b ABA008
991    __
$a 20221007152657 $b ABA008
999    __
$a min $b bmc $g 1845924 $s 1174433
BAS    __
$a 3 $a 4
BMC    __
$a 2022 $b 67 $c 6 $d 271-297 $i 0375-8427 $m Veterinární medicína $x MED00177041
LZP    __
$a NLK 2022-18/kv

Najít záznam

Citační ukazatele

Možnosti archivace